The latest news from academia, regulators
research labs and other things of interest
Posted: July 21, 2009
Quantum dots monitor changes in cancer cells
(Nanowerk News) One of the earliest events that changes a normal cell into a malignant one is known as deoxyribonucleic acid (DNA) hypermethylation, a biochemical alteration that inactivates critical tumor-suppressor genes. A team of investigators at Johns Hopkins University has developed a quantum dot-based method that can quantify DNA methylation in premalignant cells harvested from human patients.
The MS-qFRET process starts by treating sample DNA with sodium bisulfite, which converts all unmethylated cytosines (one of the four nucleic acid components of DNA) into uracil, leaving any methylated cytosines unchanged. The treated DNA then is amplified using a modified polymerase chain reaction procedure that differentiates between methylated and unmethylated DNA. This procedure also introduces fluorescent markers and biotin molecules on each piece of methylated DNA. Finally, streptavidin-coated quantum dots are added to the amplified DNA, binding tightly to the biotin-linked DNA molecules.
Quantification of methylated DNA occurs by the FRET process, in which energy transfers between the fluorescent molecule and the nearby quantum dot. The amount of fluorescence quenching, measured using confocal microscopy, provides a sensitive and accurate measure of DNA methylation. The technique is sensitive enough to enable the investigators to monitor methylation changes after premalignant cells are treated with drugs known to alter methylation patterns. The researchers also note that this technique is amenable to multiplexing, which affords the opportunity to compare multiple samples from the same patient.